

CLAIMS

1. A method for targeting a target nucleotide sequence, the method comprising introducing into a cell:
 - 5 (i) CRISPR type I-D associated proteins Cas5d, Cas6d and Cas7d, or nucleic acids encoding the proteins, and
 - (ii) a guide RNA comprising a sequence complementary to the target nucleotide sequence, and common repetitive sequences derived from a CRISPR locus, preceding and
 - 10 following the complementary sequence, or a DNA encoding the guide RNA.
2. A method for altering a target nucleotide sequence, the method comprising introducing into a cell:
 - 15 (i) CRISPR type I-D associated proteins Cas3d, Cas5d, Cas6d, Cas7d and Cas10d, or nucleic acids encoding the proteins, and
 - (ii) a guide RNA comprising a sequence complementary to the target nucleotide sequence, and common repetitive
 - 20 sequences derived from a CRISPR locus, preceding and following the complementary sequence, or a DNA encoding the guide RNA.
3. A method for suppressing the expression of a target
- 25 gene, the method comprising introducing into a cell:
 - (i) CRISPR type I-D associated proteins Cas5d, Cas6d and Cas7d, or nucleic acids encoding the proteins, and
 - (ii) a guide RNA comprising a sequence complementary to at least a part of the target gene sequence, and common
 - 30 repetitive sequences derived from a CRISPR locus, preceding and following the complementary sequence, or a DNA encoding the guide RNA.

4. The method according to any one of claims 1 to 3, wherein the guide RNA comprises a sequence consisting of 20 to 50 nucleotides which is complementary to the target nucleotide sequence.

5

5. The method according to claim 2 or 4, further comprising introducing a donor polynucleotide into the cell.

6. The method according to any one of claims 2, 4 and 5, wherein the alteration is nucleotide deletion, insertion, or substitution.

7. The method according to any one of claims 1 to 6, wherein the Cas5d recognizes 5'-GTH-3' (H = A, C, or T) as a protospacer adjacent motif (PAM) sequence.

8. A complex comprising:

(i) CRISPR type I-D associated proteins Cas5d, Cas6d and Cas7d, and

(ii) a guide RNA comprising a sequence complementary to a target nucleotide sequence, and common repetitive sequences derived from a CRISPR locus, preceding and following the complementary sequence.

9. The complex according to claim 8, further comprising Cas3d and Cas10d.

10. The complex according to claim 8 or 9, wherein the guide RNA comprises a sequence consisting of 20 to 50 nucleotides which is complementary to the target nucleotide sequence.

11. An expression vector comprising:

(i) nucleic acids encoding CRISPR type I-D associated proteins Cas5d, Cas6d and Cas7d, and

(ii) a DNA encoding a guide RNA comprising a sequence complementary to a target nucleotide sequence, and common
5 repetitive sequences derived from a CRISPR locus, preceding and following the complementary sequence.

12. The expression vector according to claim 11, further comprising nucleic acids encoding Cas3d and Cas10d.

10

13. A DNA molecule encoding the complex according to any one of claims 8 to 10.